2'-methylidene-2,3-ethano-(5α)-cholestane

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2'-methylidene-2,3-ethano-(5α)-cholestane
• 英文别名: (1S,2S,9S,12R,13S,16R,17R)-2,17-dimethyl-16-[(2R)-6-methylheptan-2-yl]-6-methylidenepentacyclo[10.7.0.02,9.04,7.013,17]nonadecane
• 化学式: C₃₀H₅₀
• 分子量: 410.727
• InChiKey: BXESSTUWMRIFSP-PMERTVAWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2'-methylidene-2,3-ethano-(5α)-cholestane 在 二氯二茂锆 、 氘代盐酸 作用下， 以 正己烷 、 重水 为溶剂， 反应 8.0h， 生成 2'-(2-deuterioethyl)-2'-deuteriomethyl-2,3-ethano-(5α)-cholestane
  参考文献：
  名称：

  Catalytic cycloalumination in steroid chemistry II: Selective functionalization of 2′-methylidene-2′,3′-ethano-(5α)-cholestane

  摘要：

  The catalytic cycloalumination of 2'-methylidene-2',3'-ethano-(5 alpha)-cholestane with Et3Al catalyzed by Cp2ZrCl2 was performed for the first time to give spiro[2',3'-ethano-(5 alpha)-cholestane-2',3 ''-aluminacyclopentane] in a similar to 75% yield and with high stereoselectivity (>98%). The obtained cyclic organoaluminum compound was transformed in situ into heterocyclic spiran derivatives of 2',3'-ethano-(5 alpha)-cholestane. (C) 2013 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2013.09.007
• 作为产物：
  描述：

  3β-胆甾烷醇 在 potassium tert-butylate 、 锌 作用下， 以 二甲基亚砜 为溶剂， 反应 13.0h， 生成 2'-methylidene-2,3-ethano-(5α)-cholestane
  参考文献：
  名称：

  Catalytic cycloalumination in steroid chemistry II: Selective functionalization of 2′-methylidene-2′,3′-ethano-(5α)-cholestane

  摘要：

  The catalytic cycloalumination of 2'-methylidene-2',3'-ethano-(5 alpha)-cholestane with Et3Al catalyzed by Cp2ZrCl2 was performed for the first time to give spiro[2',3'-ethano-(5 alpha)-cholestane-2',3 ''-aluminacyclopentane] in a similar to 75% yield and with high stereoselectivity (>98%). The obtained cyclic organoaluminum compound was transformed in situ into heterocyclic spiran derivatives of 2',3'-ethano-(5 alpha)-cholestane. (C) 2013 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2013.09.007